Scarica l'app Stockscreener
36.22
0.61%
0.22
Precedente Chiudi:
$36.00
Aprire:
$36.04
Volume 24 ore:
1.63M
Relative Volume:
1.99
Capitalizzazione di mercato:
$1.95B
Reddito:
-
Utile/perdita netta:
$-119.95M
Rapporto P/E:
-18.00
EPS:
-2.0123
Flusso di cassa netto:
$-95.28M
1 W Prestazione:
+3.37%
1M Prestazione:
+29.40%
6M Prestazione:
+189.30%
1 anno Prestazione:
+237.24%
Intervallo 1D:
$34.00
$36.96
Intervallo di 1 settimana:
$33.20
$36.96
Portata 52W:
$6.42
$36.96
Tyra Biosciences Inc Stock (TYRA) Company Profile
Nome
Tyra Biosciences Inc
Settore
Industria
Telefono
(619) 728-4760
Indirizzo
2656 STATE STREET, CARLSBAD
Compare TYRA vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TYRA
Tyra Biosciences Inc
|
36.22 | 1.95B | 0 | -119.95M | -95.28M | -2.0123 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.34 | 119.23B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.77 | 78.84B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
700.45 | 43.35B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.41 | 41.57B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.05 | 31.51B | 5.36B | 287.73M | 924.18M | 2.5229 |
Tyra Biosciences Inc Stock (TYRA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-24 | Iniziato | Cantor Fitzgerald | Overweight |
| 2026-02-10 | Iniziato | William Blair | Outperform |
| 2026-01-28 | Iniziato | Barclays | Overweight |
| 2025-09-03 | Iniziato | Raymond James | Strong Buy |
| 2025-05-21 | Ripresa | Piper Sandler | Overweight |
| 2025-01-07 | Iniziato | UBS | Buy |
| 2024-10-18 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2024-08-15 | Iniziato | Piper Sandler | Overweight |
| 2023-12-15 | Downgrade | BofA Securities | Buy → Neutral |
| 2023-06-30 | Iniziato | Wedbush | Outperform |
| 2023-02-03 | Iniziato | Oppenheimer | Outperform |
| 2022-06-23 | Iniziato | H.C. Wainwright | Buy |
| 2022-03-08 | Aggiornamento | Jefferies | Hold → Buy |
| 2021-11-08 | Downgrade | Jefferies | Buy → Hold |
| 2021-10-11 | Iniziato | BofA Securities | Buy |
| 2021-10-11 | Iniziato | Cowen | Outperform |
| 2021-10-11 | Iniziato | Jefferies | Buy |
Mostra tutto
Tyra Biosciences Inc Borsa (TYRA) Ultime notizie
Wedbush maintains Tyra Biosciences (TYRA) outperform recommendation - MSN
Tyra Biosciences stock hits all-time high at 36.69 USD By Investing.com - Investing.com Canada
Tyra Biosciences stock hits all-time high at 36.69 USD - Investing.com
ACMG meeting attendance advances FGFR3 inhibition work, Tyra Biosciences outlines - Traders Union
Tyra Biosciences (NASDAQ:TYRA) Sets New 12-Month HighHere's What Happened - MarketBeat
Trading the Move, Not the Narrative: (TYRA) Edition - Stock Traders Daily
Assessing Tyra Biosciences (TYRA) Valuation After Wider Full Year Loss And Earnings Update - Sahm
TD Cowen Maintains TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating - 富途牛牛
Tyra Biosciences, Inc. (NASDAQ:TYRA) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Aug Technicals: Is Tyra Biosciences Incs ROE strong enoughQuarterly Earnings Summary & Free Real-Time Market Sentiment Alerts - baoquankhu1.vn
Update Recap: Is Tyra Biosciences Inc a strong candidate for buy and holdJuly 2025 Macro Moves & Free Community Consensus Stock Picks - baoquankhu1.vn
Assessing Tyra Biosciences (TYRA) Valuation After William Blair Coverage And Dabogratinib Progress - Sahm
Is Tyra Biosciences Inc stock undervalued right nowJuly 2025 Closing Moves & Growth Focused Stock Reports - baoquankhu1.vn
RA Capital discloses 21.2% Tyra Biosciences (TYRA) stake after dilution - Stock Titan
Tyra Biosciences stock reaches all-time high at 35.75 USD By Investing.com - Investing.com Australia
HC Wainwright Issues Optimistic Forecast for TYRA Earnings - Defense World
Tyra Biosciences stock reaches all-time high at 35.75 USD - Investing.com Nigeria
HC Wainwright Boosts Earnings Estimates for Tyra Biosciences - MarketBeat
Tyra Biosciences (NASDAQ:TYRA) Sets New 1-Year HighHere's Why - MarketBeat
Growth Stocks To Keep An Eye On – March 3rd - Defense World
Tyra Bioscience Raises $126 Million in Block Share Sale - TipRanks
Tyra Biosciences announces $126 million stock sale in block transaction - Investing.com Australia
Tyra Biosciences announces $126 million stock sale in block transaction By Investing.com - Investing.com Nigeria
According to the latest filing from the U.S. Securities and Exchange Commission (SEC), biotechnology company Tyra Biosciences has reached an agreement to privately issue 4 million common shares to a major investment management firm. - Bitget
Tyra Biosciences agreed to issue 4 million shares at $31.50 per share to a large investment management firmSEC filing - marketscreener.com
Tyra Biosciences Agreed To Issue 4 Million Shares At $31.50 Per Share To A Large Investment Management FirmSEC Filing - TradingView
Tyra Bios to sell 4.0M shares at $31.50 in $126M ATM block transaction - TradingView
Tyra Biosciences (NASDAQ:TYRA) Shares Down 6.4%Here's What Happened - MarketBeat
TYRA: Oral Dabogratinib targets blockbuster potential in UTUC, NMIBC, and achondroplasia with pivotal data ahead - TradingView
TYRA: Oral dabogratinib targets blockbuster opportunities in UTUC, NMIBC, and achondroplasia - TradingView
Did Deeper Losses and Dabogratinib Progress Just Shift Tyra Biosciences' (TYRA) Investment Narrative? - Yahoo Finance
Oppenheimer Maintains TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating, Maintains Target Price $50 - 富途牛牛
H.C. Wainwright reiterates Tyra Biosciences stock rating at buy By Investing.com - Investing.com Canada
TYRA Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Tyra Biosciences Q4 Loss Widens - marketscreener.com
Tyra Biosciences 10-K: Net loss $119.95M, EPS $(2.01) - TradingView
Tyra Biosciences (NASDAQ: TYRA) maps FGFR oncology and achondroplasia pipeline - Stock Titan
Tyra Biosciences (Nasdaq: TYRA) boosts R&D and outlines 2026 trial catalysts - Stock Titan
Tyra Biosciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Highlights - PR Newswire
Tyra Biosciences Narrows Dabogratinib Focus, Teases Mid-Year NMIBC and 2H Achondroplasia Data - MarketBeat
TYRATyra Biosciences, Inc. Latest Stock News & Market Updates - Stock Titan
Nasdaq Moves: What are the risks of holding Tyra Biosciences Inc2025 Market WrapUp & Stepwise Trade Execution Plans - baoquankhu1.vn
TYRA SEC FilingsTyra Biosciences, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Tyra Biosciences (TYRA) Valuation Under Review After ASCO Catalysts And Positive Analyst Attention - simplywall.st
Aug Swings: Is Tyra Biosciences Inc stock undervalued right nowMarket Risk Report & Scalable Portfolio Growth Methods - baoquankhu1.vn
CEO Change: Is Tyra Biosciences Inc stock undervalued right nowPortfolio Growth Summary & Low Drawdown Investment Strategies - baoquankhu1.vn
TYRA Should I Buy - Intellectia AI
Tyra Biosciences, Inc. (TYRA) Stock Analysis: 48.56% Upside Potential Amid Strong Buy Ratings - DirectorsTalk Interviews
(TYRA) Volatility Zones as Tactical Triggers - Stock Traders Daily
TYRA: Phase II trials for dabogratinib target NMIBC, UTUC, and achondroplasia, with key data due this year - TradingView
TYRA: FGFR3-targeted trials advance in NMIBC, achondroplasia, and UTUC, with key data expected this year - TradingView
Tyra Biosciences Inc Azioni (TYRA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.48%
1.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):